I'm a Pathologist. PCOS Is a Metabolic Disease. Ozempic and Mounjaro Just Proved It.

Women with PCOS are losing weight on Ozempic and Mounjaro. But that success can make one important part of the condition easier to miss. In May 2026, an international consensus published in The Lancet renamed PCOS as PMOS (Polyendocrine Metabolic Ovarian Syndrome). I cover the 90-year history behind the old name, the insulin-androgen feedback loop that helps drive the condition, what semaglutide and tirzepatide improve, what they may not address, why endometrial protection can still matter, the truth about berberine, inositol, and peptides, and the four rules I'd give any woman with this condition. The GLP-1 Method. Waitlist (Free): ???? https://getuninflamed.com CHAPTERS 00:00 The 90-Year Medical Mistake 03:27 How PCOS Became an Ovarian Disease 06:09 The Two Hormone Loops Driving PMOS 08:22 What Your Skin Can Reveal 10:17 The Hidden Inflammation 11:45 What Weight-Loss Medications Get Right 13:56 The Anti-Inflammatory Effect Beyond Weight Loss 15:08 The Uncertain Effect on Testosterone 17:32 The Endometrial Risk Weight Loss Misses 20:31 Supplements and Peptide Marketing Claims 24:12 What the Evidence Still Can't Answer 25:25 Four Rules for Protecting Your Health 28:10 Treating the Whole Condition ABOUT ME I'm Dr. Amin Hedayat, MD, a triple board-certified pathologist and dermatopathologist with additional training in obesity medicine. I make evidence-based videos connecting pathology with metabolic health. DISCLAIMER This video is educational only, not medical advice, diagnosis, or treatment. Do not start, stop, or change any medication based on this video. Every medication decision belongs to you and your physician. REFERENCES 1. Azziz R, Adashi EY. Am J Obstet Gynecol. 2016. https://doi.org/10.1016/j.ajog.2015.12.013 2. PMOS global consensus. The Lancet. 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext 3. WHO PCOS fact sheet. 2026. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome 4. Stener-Victorin E, et al. Nat Rev Dis Primers. 2024. https://doi.org/10.1038/s41572-024-00511-3 5. Acanthosis nigricans. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK431057/ 6. Escobar-Morreale HF, et al. Fertil Steril. 2011. https://doi.org/10.1016/j.fertnstert.2010.11.036 7. Lin S, et al. Sci Rep. 2025. https://doi.org/10.1038/s41598-025-99622-4 8. Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2206038 9. Mosenzon O, et al. Cardiovasc Diabetol. 2022. https://doi.org/10.1186/s12933-022-01585-7 10. Morais BA, et al. J Diabetes Complications. 2024. https://doi.org/10.1016/j.jdiacomp.2024.108834 11. Barry JA, et al. Hum Reprod Update. 2014. https://doi.org/10.1093/humupd/dmu012 12. Khalenko VV, et al. Acta Biomed. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10210553/ 13. Teede HJ, et al. 2023 International PCOS Guideline. https://www.monash.edu/__data/assets/pdf_file/0003/3371133/PCOS-Guideline-Summary-2023.pdf 14. PCOS update. Cleve Clin J Med. 2026. https://www.ccjm.org/content/93/3/176 15. Elahi Vahed I, et al. Int J Obes. 2026. https://doi.org/10.1038/s41366-025-01943-x 16. Wilding JPH, et al. STEP 1. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2032183 17. Berberine marketplace potency testing, 33 products (commissioned by NOW; verified by Alkemist Labs). https://nutraceuticalbusinessreview.com/berberine-test-results-reveal-serious-quality-problems-from 18. NCCIH. Berberine and weight loss. https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know 19. Fitz V, et al. J Clin Endocrinol Metab. 2024. https://doi.org/10.1210/clinem/dgad762 20. FDA Compounding Advisory Committee, Jul 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 21. EGRIFTA SV (tesamorelin) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s012s013lbl.pdf 22. GEREF (sermorelin) withdrawal, Federal Register 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams 23. Eli Lilly. Retatrutide TRIUMPH-2/3. 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional 24. FDA. Foundayo (orforglipron) approval, Apr 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program #PCOS #Ozempic #Mounjaro #semaglutide #PMOS